Molecular Pharmacology (USA) Ltd
Molecular Pharmacology (USA), Ltd., a development stage company, develops and commercializes pain and inflammation management products primarily in Australia and the United States. The company, through its subsidiary, Molecular Pharmacology Pty. Ltd., develops analgesic and anti-inflammatory molecule, known as Tripeptofen for the treatment of common every-day pain. Its products are available in v… Read more
Market Cap & Net Worth: Molecular Pharmacology (USA) Ltd (MLPH)
Molecular Pharmacology (USA) Ltd (PINK:MLPH) has a market capitalization of $399.82K ($399.82K) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #50914 globally and #15631 in its home market, demonstrating a 300.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Molecular Pharmacology (USA) Ltd's stock price $0.00 by its total outstanding shares 999553740 (999.55 Million).
Molecular Pharmacology (USA) Ltd Market Cap History: 2015 to 2025
Molecular Pharmacology (USA) Ltd's market capitalization history from 2015 to 2025. Data shows change from $6.40 Million to $399.82K (-26.63% CAGR).
Molecular Pharmacology (USA) Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Molecular Pharmacology (USA) Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of MLPH by Market Capitalization
Companies near Molecular Pharmacology (USA) Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Molecular Pharmacology (USA) Ltd by market ranking:
- CLUS (PINK:CLUS): Ranked #1968 globally with a market cap of $8.00 Billion USD.
- Cartesian Growth Corporation II Warrant (NASDAQ:RENEW): Ranked #8546 globally with a market cap of $736.93 Million USD.
- Nh Special Purpose Acquisition 14 Co. Ltd (KQ:319400): Ranked #8994 globally with a market cap of $660.01 Million USD ( ₩966.39 Billion KRW).
- EQV Ventures Acquisition Corp. II (NYSE:EVAC): Ranked #10613 globally with a market cap of $465.51 Million USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #1968 | CLUS | PINK:CLUS | $8.00 Billion | $200.00 |
| #8546 | Cartesian Growth Corporation II Warrant | NASDAQ:RENEW | $736.93 Million | $138.87 |
| #8994 | Nh Special Purpose Acquisition 14 Co. Ltd | KQ:319400 | $660.01 Million | ₩30450.00 |
| #10613 | EQV Ventures Acquisition Corp. II | NYSE:EVAC | $465.51 Million | $10.07 |
Molecular Pharmacology (USA) Ltd Historical Marketcap From 2015 to 2025
Between 2015 and today, Molecular Pharmacology (USA) Ltd's market cap moved from $6.40 Million to $ 399.82K, with a yearly change of -26.63%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $399.82K | +300.00% |
| 2024 | $99.96K | -87.50% |
| 2023 | $799.64K | +700.00% |
| 2022 | $99.96K | 0.00% |
| 2021 | $99.96K | -94.12% |
| 2020 | $1.70 Million | +21.43% |
| 2019 | $1.40 Million | +7.69% |
| 2018 | $1.30 Million | -74.00% |
| 2017 | $5.00 Million | +316.67% |
| 2016 | $1.20 Million | -81.25% |
| 2015 | $6.40 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Molecular Pharmacology (USA) Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $399.82K USD |
| MoneyControl | $399.82K USD |
| MarketWatch | $399.82K USD |
| marketcap.company | $399.82K USD |
| Reuters | $399.82K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.